［1］SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBACAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA:A Cancer Journal for Clinicians,2021,71(3):209-249.
［2］SHETTY V,HAFNER J,SHAH P,et al.Investigation of ovarian cancer associated sialylation changes in N-linked glycopeptides by quantitative proteomics［J］.Clinical Proteomics,2012,9(1):10.
［3］MATHIEU KB,BEDI DG,THROWER SL,et al.Screening for ovarian cancer:imaging challenges and opportunities for improvement［J］.Ultrasound in Obstetrics & Gynecology,2018,51(3):293-303.
［4］SALDOVA R,WORMALD MR,DWEK RA,et al.Glycosylation changes on serum glycoproteins in ovarian cancer may contribute to disease pathogenesis［J］.Disease Markers,2008,25(4/5):219-232.
［5］YU H,SHU J,LI Z.Lectin microarrays for glycoproteomics:an overview of their use and potential［J］.Expert Review of Proteomics,2020,17(1):27-39.
［6］MASZCZAK-SENECZKO D,WIKTOR M,SKURSKA E,et al.Delivery of nucleotide sugars to the mammalian golgi:avery well (un)explained story［J］.International Journal of Molecular Sciences,2022,23(15):8648.
［7］WONG CH.Protein glycosylation:new challenges and opportunities［J］.The Journal of Organic Chemistry,2005,70(11):4219-4225.
［8］DHANISHA SS,GURUVAYOORAPPAN C,DRISHYA S,et al.Mucins:structural diversity,biosynthesis,its role in pathogenesis and as possible therapeutic targets［J］.Critical Reviews in Oncology/Hematology,2018,122:98-122.
［9］MITA Y,AOYAGI Y,SUDA T,et al.Plasma fucosyltransferase activity in patients with hepatocellular carcinoma,with special reference to correlation with fucosylated species of alpha-fetoprotein［J］.Journal of Hepatology,2000,32(6):946-954.
［10］CHEN H,DENG Z,HUANG C,et al.Mass spectrometric profiling reveals association of N-glycan patterns with epithelial ovarian cancer progression［J］.Tumour Biology,2017,39(7):1010428317716249.
［11］DUBE DH,BERTOZZI CR.Glycans in cancer and inflammation-potential for therapeutics and diagnostics［J］.Nature Reviews Drug Discovery,2005,4(6):477-488.
［12］LEE WL,WANG PH.Aberrant sialylation in ovarian cancers［J］.Journal of The Chinese Medical Association:JCMA,2020,83(4):337-344.
［13］BERGHUIS AY,PIJNENBORG JFA,BOLTJC TJ,et al.Sialic acids in gynecological cancer development and progression:impact on diagnosis and treatment［J］.International Journal of Cancer,2022,150(4):678-687.
［14］LI F,DING J.Sialylation is involved in cell fate decision during development,reprogramming and cancer progression［J］.Protein & Cell,2019,10(8):550-565.
［15］LI Y,CHEN X.Sialic acid metabolism and sialyltransferases:natural functions and applications［J］.Applied Microbiology and Biotechnology,2012,94(4):887-905.
［16］PIETROBONO S,STECCA B.Aberrant sialylation in cancer:biomarker and potential target for therapeutic intervention［J］.Cancers,2021,13(9):2014.
［17］DOBIE C,SKROPETA D.Insights into the role of sialylation in cancer progression and metastasis［J］.British Journal of Cancer,2021,124(1):76-90.
［18］MIYOSHI E,MORIWAKI K,NAKAGAWA T.Biological function of fucosylation in cancer biology［J］.Journal of Biochemistry,2008,143(6):725-729.
［19］YANAGIDANI S,UOZUMI N,IHARA Y,et al.Purification and cDNA cloning of GDP-L-Fuc:N-acetyl-beta-D-glucosaminide:alpha1-6 fucosyltransferase (alpha1-6 FucT) from human gastric cancer MKN45 cells［J］.Journal of Biochemistry,1997,121(3):626-632.
［20］LAI TY,CHEN IJ,LIN RJ,et al.Fucosyltransferase 1 and 2 play pivotal roles in breast cancer cells［J］.Cell Death Discovery,2019,5:74.
［21］LIAO C,AN J,YI S,et al.FUT8 and protein core fucosylation in tumours:from diagnosis to treatment［J］.Journal of Cancer,2021,12(13):4109-4120.
［22］BLANAS A,SAHASRABUDHE NM,RODRIGUEZ E,et al.Fucosylated antigens in cancer:an alliance toward tumor progression,metastasis,and resistance to chemotherapy［J］.Frontiers in Oncology,2018,8:39.
［23］ZHANG Z,WUHRER M,HOLST S.Serum sialylation changes in cancer［J］.Glycoconjugate Journal,2018,35(2):139-160.
［24］BERBEC H,PASZKOWSKA A,SIWEK B,et al.Total serum sialic acid concentration as a supporting marker of malignancy in ovarian neoplasia［J］.European Journal of Gynaecological Oncology,1999,20(5/6):389-392.
［25］WANG PH,LEE WL,JUANG CM,et al.Altered mRNA expressions of sialyltransferases in ovarian cancers［J］.Gynecologic Oncology,2005,99(3):631-639.
［26］SUNG PL,WEN KC,HORNG HC,et al.The role of α2,3-linked sialylation on clear cell type epithelial ovarian cancer［J］.Taiwanese Journal of Obstetrics & Gynecology,2018,57(2):255-263.
［27］WEN KC,SUNG PL,HSIEH SL,et al.α2,3-sialyltransferase type I regulates migration and peritoneal dissemination of ovarian cancer cells［J］.Oncotarget,2017,8(17):29013-29027.
［28］WICHERT B,MILDE-LANGOSCH K,GALATENKO V,et al.Prognostic role of the sialyltransferase ST6GAL1 in ovarian cancer［J］.Glycobiology,2018,28(11):898-903.
［29］CHRISTIC DR,SHAIKH FM,LUCAS JA,et al.ST6Gal-I expression in ovarian cancer cells promotes an invasive phenotype by altering integrin glycosylation and function［J］.Journal of Ovarian Research,2008,1(1):3.
［30］SCHULTZ MJ,HOLDBROOKS AT,CHAKRABORTY A,et al.The tumor-associated glycosyltransferase ST6Gal-I regulates stem cell transcription factors and Cconfers a cancer stem cell phenotype［J］.Cancer Research,2016,76(13):3978-3988.
［31］SCHULTZ MJ,SWINDALL AF,WRIGHT JW,et al.ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells［J］.Journal of Ovarian Research,2013,6(1):25.
［32］BRITAIN CM,HOLDBROOKS AT,ANDERSON JC,et al.Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death［J］.Journal of Ovarian Research,2018,11(1):12.
［33］OU L,HE X,LIU N,et al.Sialylation of FGFR1 by ST6Gal-I overexpression contributes to ovarian cancer cell migration and chemoresistance［J］.Molecular Medicine Reports,2020,21(3):1449-1460.
［34］WIECZOREK M,BRAICU EI,OLIVEIRA-FERRER L,et al.Immunoglobulin G subclass-specific glycosylation changes in primary epithelial ovarian cancer［J］.Frontiers in Immunology,2020,11:654.
［35］FOURNIER T,MEDJOUBI-N N,PORQUET D.Alpha-1-acid glycoprotein［J］.Biochimica Et Biophysica Acta,2000,1482(1-2):157-171.
［36］RODRIGUEZ E,SCHETTERS STT,VAN KOOYK Y.The tumour glyco-code as a novel immune checkpoint for immunotherapy［J］.Nature Reviews Immunology,2018,18(3):204-211.
［37］STARBUCK K,AL-ALEM L,EAVARONE DA,et al.Treatment of ovarian cancer by targeting the tumor stem cell-associated carbohydrate antigen,sialyl-thomsen-nouveau［J］.Oncotarget,2018,9(33):23289-23305.
［38］DORSETT KA,JONES RB,ANKENBAUER KE,et al.Sox2 promotes expression of the ST6Gal-I glycosyltransferase in ovarian cancer cells［J］.Journal of Ovarian Research,2019,12(1):93.
［39］ESCREVENTE C,MACHADO E,BRITO C,et al.Different expression levels of alpha3/4 fucosyltransferases and Lewis determinants in ovarian carcinoma tissues and cell lines［J］.International Journal of Oncology,2006,29(3):557-566.
［40］CHANDRASEKARAN EV,JAIN RK,MATTA KL.Ovarian cancer alpha 1,3-L-fucosyltransferase.differentiation of distinct catalytic species with the unique substrate,3'-sulfo-N-acetyllactosamine in conjunction with other synthetic acceptors［J］.The Journal of Biological Chemistry,1992,267(33):23806-23814.
［41］BEREMAN MS,WILLIAMS TI,MUDDIMAN DC.Development of a nanoLC LTQ orbitrap mass spectrometric method for profiling glycans derived from plasma from healthy,benign tumor control,and epithelial ovarian cancer patients［J］.Analytical Chemistry,2009,81(3):1130-1136.
［42］BRIGGS MT,CONDINA MR,HO YY,et al.MALDI mass spectrometry imaging of early- and late-stage serous ovarian cancer tissue reveals stage-specific N-Glycans［J］.Proteomics,2019,19(21/22):e1800482.
［43］CAMERON HS,SZCZEPANIAK D,WESTON BW.Expression of human chromosome 19p alpha(1,3)-fucosyltransferase genes in normal tissues:alternative splicing,polyadenylation,and isoforms［J］.The Journal of Biological Chemistry,1995,270(34):20112-20122.
［44］PATCH AM,CHRISTIE EL,ETEMADMOGHADAM D,et al.Whole-genome characterization of chemoresistant ovarian cancer［J］.Nature,2015,521(7553):489-494.
［45］OSUMI D,TAKAHASHI M,MIYOSHI E,et al.Core fucosylation of E-cadherin enhances cell-cell adhesion in human colon carcinoma WiDr cells［J］.Cancer Science,2009,100(5):888-895.
［46］LYU X,SONG J,XUE K,et al.Core fucosylation of copper transporter 1 plays a crucial role in cisplatin-resistance of epithelial ovarian cancer by regulating drug uptake［J］.Molecular Carcinogenesis,2019,58(5):794-807.
［47］ZHAO R,QIN W,QIN R,et al.Lectin array and glycogene expression analyses of ovarian cancer cell line A2780 and its cisplatin-resistant derivate cell line A2780-cp［J］.Clinical Proteomics,2017,14:20.
［48］LIN G,ZHAO R,WANG Y,et al.Dynamic analysis of N-glycomic and transcriptomic changes in the development of ovarian cancer cell line A2780 to its three cisplatin-resistant variants［J］.Annals of Translational Medicine,2020,8(6):289.
［49］LI FF,SHA D,QIN XY,et al.Alpha1,2-fucosyl transferase gene,the key enzyme of Lewis y synthesis,promotes Taxol resistance of ovarian carcinoma through apoptosis-related proteins［J］.Neoplasma,2018,65(4):515-522.
［50］ZHAO R,LIU X,WANG Y,et al.Integrated glycomic analysis of ovarian cancer side population cells［J］.Clinical Proteomics,2016,13:32.
［51］JIN S,GAO J,QI Y,et al.TGF-β1 fucosylation enhances the autophagy and mitophagy via PI3K/Akt and Ras-Raf-MEK-ERK in ovarian carcinoma［J］.Biochemical and Biophysical Research Communications,2020,524(4):970-976.
［52］ZHUANG H,HU Z,TAN M,et al.Overexpression of lewis y antigen promotes human epididymis protein 4-mediated invasion and metastasis of ovarian cancer cells［J］.Biochimie,2014,105:91-98.
［53］IWAMORI M,TANAKA K,KUBUSHIRO K,et al.Alterations in the glycolipid composition and cellular properties of ovarian carcinoma-derived RMG-1 cells on transfection of the alpha1,2-fucosyltransferase gene［J］.Cancer Science,2005,96(1):26-30.
［54］KUZMANOV U,MUSRAP N,KOSANAM H,et al.Glycoproteomic identification of potential glycoprotein biomarkers in ovarian cancer proximal fluids［J］.Clinical Chemistry and Laboratory Medicine,2013,51(7):1467-1476.
［55］WU J,XIE X,NIE S,et al.Altered expression of sialylated glycoproteins in ovarian cancer sera using lectin-based ELISA assay and quantitative glycoproteomics analysis［J］.Journal of Proteome Research,2013,12(7):3342-3352.
［56］DEDOVA T,BRAICU EI,SEHOULI J,et al.Sialic acid linkage analysis refines the diagnosis of ovarian cancer［J］.Frontiers in Oncology,2019,9:261.
［57］BISKUP K,BRAICU EI,SEHOULI J,et al.Serum glycome profiling:a biomarker for diagnosis of ovarian cancer［J］.Journal of Proteome Research,2013,12(9):4056-4063.
［58］MIYAMOTO S,RUHAAK LR,STROBLE C,et al.Glycoproteomic analysis of malignant ovarian cancer ascites fluid identifies unusual glycopeptides［J］.Journal of Proteome Research,2016,15(9):3358-3376.
［59］ALBERTO-AGUILAR DR,HERNANDEZ-RAMIREZ VI,OSORIO-TRUJILLO JC,et al.Ascites from ovarian cancer induces novel fucosylated proteins［J］.Cancer Microenvironment,2019,12(2/3):181-195.
［60］DWIVEDI C,DIXIT M,HARDY RE.Plasma sialyltransferase as a tumor marker［J］.Cancer Detection and Prevention,1988,11(3/6):191-196.
［61］KOBAYASHI H,TERAO T,KAWASHIMA Y.Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer［J］.Journal of Clinical Oncology,1992,10(1):95-101.
［62］LIU J,LIU Q,WANG Y,et al.Co-expression of lewis y antigen and CD147 in epithelial ovarian cancer is correlated with malignant progression and poor prognosis［J］.International Journal of Molecular Medicine,2019,43(4):1687-1698.
［63］ALBERTO-AGUILAR DR,HERNANDEZ-RAMIREZ VI,OSORIO-TRUJILLO JC,et al.PHD finger protein 20-like protein 1 (PHF20L1) in ovarian cancer:from its overexpression in tissue to its upregulation by the ascites microenvironment［J］.Cancer Cell International,2022,22(1):6.
［64］THOMPSON S,GUTHRIE D,TURNER GA.Fucosylated forms of alpha-1-antitrypsin that predict unresponsiveness to chemotherapy in ovarian cancer［J］.British Journal of Cancer,1988,58(5):589-593.
［65］HUANG W,SUN L,WANG B,et al.Ginsenosides,potent inhibitors of sialyltransferase［J］.Zeitschrift Fur Naturforschung C,Journal of Biosciences,2020,75(1/2):41-49.
［66］BIFFI S,VOLTAN R,RAMPAZZO E,et al.Applications of nanoparticles in cancer medicine and beyond:optical and multimodal in vivo imaging,tissue targeting and drug delivery［J］.Expert Opinion on Drug Delivery,2015,12(12):1837-1849.
［67］HALBUR C,CHOUDHURY N,CHEN M,et al.siRNA-conjugated nanoparticles to treat ovarian cancer［J］.Slas Technology,2019,24(2):137-150.
［68］HOLMBERG LA,OPARIN DV,GOOLEY T,et al.The role of cancer vaccines following autologous stem cell rescue in breast and ovarian cancer patients:experience with the STn-KLH vaccine (Theratope)［J］.Clinical Breast Cancer,2003,3(Suppl 4):S144-S151.
［69］DISIS ML,CORULLI LR,GAD EA,et al.Therapeutic and prophylactic antitumor activity of an oral inhibitor of fucosylation in spontaneous mammary cancers［J］.Molecular Cancer Therapeutics,2020,19(5):1102-1109.